The University of Wisconsin Carbone Cancer Center (UWCCC) is comprised of 216 research members from 45 departments and 11 schools of the University of Wisconsin Madison. UW-Madison has a long and rich history as an international leader in basic, translational and clinical cancer research reflected in its history of two NCI-designated and -funded cancer research centers founded by Dr. Harold Rusch on the UW-Madison campus. The McArdle Laboratory for Cancer Research was founded in 1940 and received its initial NCI funding in 1946. UWCCC has received continuous NCI funding since 1973 when it was awarded NCI funding as one of the first six comprehensive cancer centers. After a coordinated process during the late 1990's, both centers were consolidated under UWCCC in 2001 when the first NCI Cancer Center Support Grant representing the consolidated centers was awarded. The consolidation of the two centers has generated tremendous enthusiasm and growth for cancer research on the UW-Madison campus over the past ten years. This has resulted in a Center greater than the sum of the two parts existing before the consolidation. With the completion of the Wisconsin Institutes of Medical Research (WIMR) Tower 1 in 2008 and with Tower 2 completion projected for 2013, UWCCC will have approximately 350,000 sq ft of contiguous space dedicated to cancer clinical care and research, a nearly three-fold increase over the past ten years. In addition, the new Wisconsin Institutes of Discovery (WID), a $200 million UW-Madison central campus research facility that also includes the privately-operated Morgridge Institute for Research (MIR), opened in 2011. WID/MIR will house 10 focused research teams of four or more faculty each. Five of these teams are led by UWCCC members representing a strong cancer research presence in the WID/MIR. Three quarters of the faculty in WID will be new recruits to UW-Madison. The three future highest goals of UWCCC are unchanged from the current goals: 1) to conduct the highest quality research into the origins and control of cancer;2) to translate these research findings to evaluation in the clinic through well-designed clinical trials with corresponding biologic endpoint whenever possible;and 3) to provide the best care possible to all cancer patients by carefully integrating high quality, cutting-edge care with clinical research in a compassionate and individualized manner. UWCCC has $30.7 million in NCI funding (direct) and a total of $83.7 million cancer focused research funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014520-39S2
Application #
8719208
Study Section
Subcommittee G - Education (NCI)
Program Officer
Adjei, Brenda A
Project Start
1997-04-25
Project End
2018-03-31
Budget Start
2013-04-12
Budget End
2014-03-31
Support Year
39
Fiscal Year
2013
Total Cost
$122,414
Indirect Cost
$32,404
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Shiyanbola, Oyewale O; Sprague, Brian L; Hampton, John M et al. (2016) Emerging trends in surgical and adjuvant radiation therapies among women diagnosed with ductal carcinoma in situ. Cancer 122:2810-8
Valeri, Linda; Chen, Jarvis T; Garcia-Albeniz, Xabier et al. (2016) The Role of Stage at Diagnosis in Colorectal Cancer Black-White Survival Disparities: A Counterfactual Causal Inference Approach. Cancer Epidemiol Biomarkers Prev 25:83-9
Lu, Weifei; Hong, Hao; Cai, Weibo (2016) Radio-nanomaterials for biomedical applications: state of the art. Eur J Nanomed 8:151-170
Moore, Robert W; Fritz, Wayne A; Schneider, Andrew J et al. (2016) 2,3,7,8-Tetrachlorodibenzo-p-dioxin has both pro-carcinogenic and anti-carcinogenic effects on neuroendocrine prostate carcinoma formation in TRAMP mice. Toxicol Appl Pharmacol 305:242-9
Lor, Maichou; Xiong, Phia; Park, Linda et al. (2016) Western or Traditional Healers? Understanding Decision Making in the Hmong Population. West J Nurs Res :
Chang, Julie E; Havighurst, Thomas; Kim, KyungMann et al. (2016) Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study. Br J Haematol 173:283-91
Guckenberger, David J; Pezzi, Hannah M; Regier, Mary C et al. (2016) Magnetic System for Automated Manipulation of Paramagnetic Particles. Anal Chem :
Hernandez, Reinier; Sun, Haiyan; England, Christopher G et al. (2016) CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody. Theranostics 6:1918-33
Damnernsawad, Alisa; Kong, Guangyao; Wen, Zhi et al. (2016) Kras is Required for Adult Hematopoiesis. Stem Cells 34:1859-71
Zhan, Yonghua; Ai, Fanrong; Chen, Feng et al. (2016) Intrinsically Zirconium-89 Labeled Gd2 O2 S:Eu Nanoprobes for In Vivo Positron Emission Tomography and Gamma-Ray-Induced Radioluminescence Imaging. Small 12:2872-6

Showing the most recent 10 out of 1196 publications